<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>37</patient-age><report-id>PHHY2012BR103528</report-id><gender>female</gender><reactions><reaction>Bone necrosis in the shoulders and hip</reaction><reaction>Back pain /The patient walked and she breathed deeply she felt a lot of back pain and breathlessness</reaction><reaction>The patient walked and she breathed deeply she felt a lot of back pain and breathlessness</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>FORASEQ</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>ALENIA</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TRAMAL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>TYLENOL</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>PURAN T4</drug-name><manufacturer/><ingredients/></drug><drug><ndc>59572983</ndc><drug-name>CALCIUM + VITAMIN D</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Asthma</indication><indication>Pain</indication><indication>Thyroid disorder</indication><indication>Bone decalcification</indication></indications><outcomes><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Brazil</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053099_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211133611</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>3</safetyreportversion>
		<safetyreportid>PHHY2012BR103528</safetyreportid>
		<primarysourcecountry>BR</primarysourcecountry>
		<occurcountry>BR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>2</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>1</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-11-07</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-03</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012BR103528</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>BR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>RDG</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19750624</patientbirthdate>
			<patientweight>86</patientweight>
			<patientheight>173</patientheight>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Drug hypersensitivity</patientepisodename>
				<patientmedicalstartdateformat>602</patientmedicalstartdateformat>
				<patientmedicalstartdate>1995</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>The patient's medical history included, since 1995 she had drug allergy to Aspirin (acetylsalicylic </patientmedicalcomment>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Pain</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Thyroid disorder</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Bone decalcification</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Hip arthroplasty</patientepisodename>
				<patientmedicalstartdateformat>610</patientmedicalstartdateformat>
				<patientmedicalstartdate>201002</patientmedicalstartdate>
				<patientmedicalcontinue>3</patientmedicalcontinue>
				<patientmedicalcomment>The patient underwent surgery of total hip prosthesis of the right side to remove necrosis and the p</patientmedicalcomment>
			</medicalhistoryepisode>
			<reaction>
				<primarysourcereaction>Bone necrosis in the shoulders and hip</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Bone necrosis</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Osteonecrosis</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>Back pain /The patient walked and she breathed deeply she felt a lot of back pain and breathlessness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Back pain</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Back pain</reactionmeddrapt>
				<reactionoutcome code="2">recovering/resolved</reactionoutcome>
			</reaction>
			<reaction>
				<primarysourcereaction>The patient walked and she breathed deeply she felt a lot of back pain and breathlessness</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Breathlessness</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Dyspnoea</reactionmeddrapt>
				<reactionoutcome code="6">unknown</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>FORASEQ</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationnumb>20-831</drugauthorizationnumb>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, QD</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Asthma</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>BUDESONIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Back pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Back pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>FORASEQ</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationnumb>20-831</drugauthorizationnumb>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>1</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, QD</drugdosagetext>
				<drugdosageform normalized="capsule">Capsule</drugdosageform>
				<drugstartdateformat>610</drugstartdateformat>
				<drugstartdate>2012-10-01</drugstartdate>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
				<activesubstance>
					<activesubstancename>BUDESONIDE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Back pain</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Back pain</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Dyspnoea</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Osteonecrosis</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>ALENIA</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>2</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, BID</drugdosagetext>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Asthma</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>BUDESONIDE, FORMOTEROL FUMARATE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TRAMAL</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>3</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, TID (every 3 hours)</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>TRAMADOL HYDROCHLORIDE</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>TYLENOL</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugseparatedosagenumb>4</drugseparatedosagenumb>
				<drugintervaldosageunitnumb>1</drugintervaldosageunitnumb>
				<drugintervaldosagedefinition code="804">Day</drugintervaldosagedefinition>
				<drugdosagetext>1 DF, QID (every 6 hours)</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Pain</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>PARACETAMOL</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>PURAN T4</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugdosagetext>1 DF, in the morning</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Thyroid disorder</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>LEVOTHYROXINE SODIUM</activesubstancename>
				</activesubstance>
			</drug>
			<drug>
				<drugcharacterization code="2">concomitant</drugcharacterization>
				<medicinalproduct>CALCIUM + VITAMIN D</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugstructuredosagenumb>1</drugstructuredosagenumb>
				<drugstructuredosageunit code="032"/>
				<drugdosagetext>1 DF, UNK</drugdosagetext>
				<drugadministrationroute code="048">Oral</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Bone decalcification</drugindication>
				<actiondrug code="4">Dose not changed</actiondrug>
				<activesubstance>
					<activesubstancename>CALCIUM CARBONATE, COLECALCIFEROL</activesubstancename>
				</activesubstance>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012BR103528, is a combined <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a consumer (patient's mother) via marketing program (ID 423-Vale Mais Saude, <Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">vendor</Semaphore>: Voxline) on 07 Nov 2012 and 08 Nov 2012, with further follow up report received from consumer (patient's mother) on 19 Nov 2012 with follow up report received from Quality Assurance Department on 03 Dec 2012. This is also a quality complaint report. This report refers to a 37-year old female patient. This poly medicated patient's medical history included <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug </Semaphore><Semaphore x="1470824" class="Disease or Finding" value="Allergic Reaction" score="1.00" ID="C114476">allergy </Semaphore>to <Semaphore x="166901" class="Medicine" value="Aspirin" score="0.49" ID="212518">Aspirin </Semaphore>(acetylsalicylic <Semaphore x="2147465" class="Procedure" value="Lysergide Measurement" score="1.00" ID="C75354">acid</Semaphore>), <Semaphore x="465181" class="Medicine" value="Diclofenac" score="0.49" ID="256353">diclofenac</Semaphore>, <Semaphore x="493397" class="Medicine" value="Dipyrone" score="0.49" ID="258262">dipyrone</Semaphore>, and <Semaphore x="1004964" class="Medicine" value="Penicillin" score="0.49" ID="280930">penicillin </Semaphore>(all since 1995), <Semaphore x="3279320" class="MedDRA LLT" value="Thyroid pain" score="1.00" ID="10043757"><Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">pain</Semaphore>, <Semaphore x="2618121" class="Disease or Finding" value="Thyroid Gland Abscess" score="1.00" ID="C27115">thyroid </Semaphore></Semaphore>
    <Semaphore x="1855439" class="Disease or Finding" value="Disfigurement" score="1.00" ID="C50536">disorder </Semaphore>and lack of <Semaphore x="287292" class="Medicine" value="Calcium" score="0.49" ID="240008">calcium </Semaphore>in <Semaphore x="1615518" class="AnatomicStructure" value="Bone Marrow" score="1.00" ID="C12431">bone</Semaphore>. This poly medicated patient received Foraseq 12/400mcg (<Semaphore x="601213" class="Medicine" value="formoterol fumarate" score="0.74" ID="249709">formoterol fumarate </Semaphore>/budesonide) capsules for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1550634" class="Disease or Finding" value="Asthma" score="1.00" ID="C28397">asthma </Semaphore>from an unspecified date (started more than 5 years ago) at a dose of once daily, inhalation route. The patient also received Alenia 12/400mcg (<Semaphore x="601213" class="Medicine" value="formoterol fumarate" score="0.74" ID="249709">formoterol fumarate </Semaphore>/ <Semaphore x="249815" class="Medicine" value="Budesonide" score="0.49" ID="238770">budesonide</Semaphore>) for the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>of <Semaphore x="1550634" class="Disease or Finding" value="Asthma" score="1.00" ID="C28397">asthma </Semaphore>from an unspecified date at a dose of twice daily, inhalation route. The reporter informed that the patient <Semaphore x="1472347" class="Disease or Finding" value="Alternative Fascicle (Bundle) Pattern" score="1.00" ID="C49119">alternated </Semaphore>the use of Foraseq 12/400mcg and Alenia 12/400mcg, and on an unspecified date the patient stopped using Foraseq 12/400mcg, but returned using it last month (Oct 2012). On an unspecified date (five years ago after starting the suspect <Semaphore x="1670730" class="Procedure" value="CAM Pharmacological or Biological Treatment" score="1.00" ID="C15906">drug</Semaphore>), the patient was <Semaphore x="1846062" class="Procedure" value="Diagnosis" score="1.00" ID="C15220">diagnosed </Semaphore>with <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880"><Semaphore x="1618654" class="AnatomicStructure" value="Bone Tissue" score="1.00" ID="C13076">bone </Semaphore>necrosis </Semaphore>in the <Semaphore x="2520062" class="AnatomicStructure" value="Shoulder" score="1.00" ID="C25203">shoulders </Semaphore>and <Semaphore x="2026507" class="AnatomicStructure" value="Hip" score="1.00" ID="C64193">hip</Semaphore>. Thus, in Feb 2010, the patient underwent <Semaphore x="3006514" class="MedDRA LLT" value="Hip surgery" score="1.00" ID="10051060"><Semaphore x="2596409" class="Procedure" value="Surgical Procedure" score="1.00" ID="C15329">surgery </Semaphore>of total <Semaphore x="2026507" class="AnatomicStructure" value="Hip" score="1.00" ID="C64193">hip </Semaphore></Semaphore>prosthesis of the right side to remove <Semaphore x="3125797" class="MedDRA LLT" value="Necrosis" score="1.00" ID="10028851">necrosis</Semaphore>. The patient was hospitalized for 15 days. On an unspecified date (two weeks ago), the patient <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.76" ID="C91103">had experienced <Semaphore x="2773719" class="MedDRA LLT" value="Back pain" score="1.00" ID="10003988">back pain</Semaphore></Semaphore>, when she <Semaphore x="1936750" class="Procedure" value="Findings-Based Question" score="0.76" ID="C91103">walked </Semaphore>and breathed deeply, she felt a lot of <Semaphore x="1563437" class="Disease or Finding" value="Back Pain" score="1.00" ID="C41830">back pain </Semaphore>and <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">breathlessness</Semaphore>. Thus, for <Semaphore x="1563437" class="Disease or Finding" value="Back Pain" score="1.00" ID="C41830">back pain </Semaphore>and <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">breathlessness</Semaphore>, the patient went to the emergency and received Tramal (<Semaphore x="1284718" class="Medicine" value="traMADol hydrochloride" score="0.49" ID="285586">tramadol hydrochloride</Semaphore>) and <Semaphore x="885260" class="Medicine" value="Morphine" score="0.49" ID="280811">morphine </Semaphore>(unknown <Semaphore x="2199623" class="Occupation" value="Manufacturer" score="1.00" ID="C25392">manufacturer</Semaphore>) and was using Benflogin (<Semaphore x="208080" class="Medicine" value="Benzydamine Hydrochloride" score="0.49" ID="285479">benzydamine hydrochloride</Semaphore>) <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">orally </Semaphore>from 01 Nov 2012 at a dose of 1 tablet every 8 hours. During follow up, it was reported that patient did not rinse the <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">mouth </Semaphore>after using Foraseq. The <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with Foraseq and Alenia was reported as ongoing. The events <Semaphore x="2353201" class="Disease or Finding" value="Outcome" score="1.00" ID="C20200">outcome </Semaphore>was reported as condition improving for <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303"><Semaphore x="1563470" class="Disease or Finding" value="Background Diabetic Retinopathy" score="1.00" ID="C34408"><Semaphore x="1563437" class="Disease or Finding" value="Back Pain" score="1.00" ID="C41830">back <Semaphore x="1618418" class="Disease or Finding" value="Bone Pain" score="1.00" ID="C38644">pain </Semaphore></Semaphore>
       <Semaphore x="2822456" class="MedDRA LLT" value="Bone pain" score="1.00" ID="10006002">
        <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">
         </Semaphore></Semaphore></Semaphore>
      <Semaphore x="2822456" class="MedDRA LLT" value="Bone pain" score="1.00" ID="10006002">
       <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">
        </Semaphore>
       </Semaphore></Semaphore>
    <Semaphore x="2365183" class="Disease or Finding" value="Pain" score="1.00" ID="C3303">
     <Semaphore x="2822456" class="MedDRA LLT" value="Bone pain" score="1.00" ID="10006002">
      <Semaphore x="1618418" class="Disease or Finding" value="Bone Pain" score="1.00" ID="C38644">and <Semaphore x="1618654" class="AnatomicStructure" value="Bone Tissue" score="1.00" ID="C13076">bone </Semaphore></Semaphore>
      <Semaphore x="3162294" class="MedDRA LLT" value="Osteonecrosis" score="1.00" ID="10031264">
       </Semaphore></Semaphore></Semaphore>
    <Semaphore x="2822456" class="MedDRA LLT" value="Bone pain" score="1.00" ID="10006002">
     <Semaphore x="3162294" class="MedDRA LLT" value="Osteonecrosis" score="1.00" ID="10031264">
      </Semaphore></Semaphore>
    <Semaphore x="3162294" class="MedDRA LLT" value="Osteonecrosis" score="1.00" ID="10031264">
     <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880">necrosis </Semaphore></Semaphore>in the <Semaphore x="2520062" class="AnatomicStructure" value="Shoulder" score="1.00" ID="C25203">shoulders </Semaphore>and <Semaphore x="2026507" class="AnatomicStructure" value="Hip" score="1.00" ID="C64193">hips </Semaphore>and for <Semaphore x="2918626" class="MedDRA LLT" value="Dyspnoea" score="1.00" ID="10013968">breathlessness </Semaphore>was not reported. The seriousness for event <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880"><Semaphore x="1618654" class="AnatomicStructure" value="Bone Tissue" score="1.00" ID="C13076">bone </Semaphore>necrosis </Semaphore>was <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>and seriousness of other event was not reported. Causality <Semaphore x="2397639" class="Procedure" value="Physical Examination" score="1.00" ID="C20989">assessment </Semaphore>of the event was not reported. Quality assurance department stated that this case was reevaluated as medical event without quality complaint.Follow up report received from consumer (patient's mother) on 19 Nov 2012: Updated event information (reported seriousness: <Semaphore x="1617802" class="Disease or Finding" value="Bone Necrosis" score="1.00" ID="C34880"><Semaphore x="1618654" class="AnatomicStructure" value="Bone Tissue" score="1.00" ID="C13076">bone </Semaphore>necrosis </Semaphore>in the <Semaphore x="2520062" class="AnatomicStructure" value="Shoulder" score="1.00" ID="C25203">shoulders </Semaphore>and <Semaphore x="2026507" class="AnatomicStructure" value="Hip" score="1.00" ID="C64193">hips </Semaphore>as <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization</Semaphore>), updated narration (patient did not rinse the <Semaphore x="2336704" class="AnatomicStructure" value="Oral Cavity" score="1.00" ID="C12421">mouth </Semaphore>after using Foraseq).Follow up report received from Quality assurance department on 03 Dec 2012: Quality assurance departments comment updated.</narrativeincludeclinical>
				<sendercomment>Based on Review of available reported data does not allow for a proper causality assessment. Reported event is unassessable.</sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>